Immunovant (IMVT)
(Delayed Data from NSDQ)
$29.23 USD
-0.36 (-1.22%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $29.22 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Cash flow Statements
Fiscal Year End for Immunovant, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -259.34 | -210.96 | -156.73 | -107.43 | -66.39 |
Depreciation/Amortization & Depletion | 0.23 | 0.19 | 0.13 | 0.07 | 0.02 |
Net Change from Assets/Liabilities | 2.63 | -10.85 | 15.14 | 4.57 | 4.81 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 42.25 | 33.43 | 35.35 | 19.47 | 8.20 |
Net Cash From Operating Activities | -214.23 | -188.19 | -106.11 | -83.33 | -53.36 |
Property & Equipment | -0.36 | -0.20 | -0.25 | -0.21 | -0.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.36 | -0.20 | -0.25 | -0.21 | -0.03 |
Uses of Funds
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 478.44 | 71.16 | 0.00 | 386.44 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 32.50 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 200.00 | -3.19 | 5.41 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -6.01 | -0.27 | 0.13 | -0.14 | 109.07 |
Net Cash from Financing Activities | 472.43 | 70.89 | 200.13 | 383.11 | 146.97 |
Effect of Exchange Rate Changes | 0.99 | 0.22 | -0.09 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 258.83 | -117.29 | 93.67 | 299.58 | 93.59 |
Cash at Beginning of Period | 376.53 | 493.82 | 400.15 | 100.57 | 6.99 |
Cash at End of Period | 635.37 | 376.53 | 493.82 | 400.15 | 100.57 |
Diluted Net EPS | -1.88 | -1.71 | -1.43 | -1.22 | -1.54 |
Fiscal Year End for Immunovant, Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -87.15 | -259.34 | -184.02 | -132.60 | -73.94 |
Depreciation/Amortization & Depletion | 0.00 | 0.23 | 0.17 | 0.11 | 0.05 |
Net Change from Assets/Liabilities | -2.65 | 2.63 | -2.99 | 3.26 | 15.54 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 13.60 | 42.25 | 32.32 | 21.80 | 10.98 |
Net Cash From Operating Activities | -76.20 | -214.23 | -154.53 | -107.43 | -47.37 |
Property & Equipment | -0.18 | -0.36 | -0.21 | -0.08 | -0.05 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -0.18 | -0.36 | -0.21 | -0.08 | -0.05 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.69 | 478.44 | 476.89 | 1.04 | 0.89 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -6.01 | -6.01 | 0.00 | 0.00 |
Net Cash from Financing Activities | 0.69 | 472.43 | 470.88 | 1.04 | 0.89 |
Effect of Exchange Rate Changes | 0.34 | 0.99 | -1.74 | -0.13 | -0.05 |
Net Change In Cash & Equivalents | -75.36 | 258.83 | 314.41 | -106.60 | -46.57 |
Cash at Beginning of Period | 635.37 | 376.53 | 376.53 | 376.53 | 376.53 |
Cash at End of Period | 560.01 | 635.37 | 690.94 | 269.93 | 329.96 |
Diluted Net EPS | -0.60 | -0.50 | -0.36 | -0.45 | -0.57 |